Low T Center endorses the recommendations of the joint FDA committee meeting in Hyattsville, Maryland, earlier this week. The FDA convened the meeting to assess the proper patient population for testosterone therapy (TRT), as well as to assess potential cardiovascular risk associated with TRT. Examining recent claims from studies that TRT affects cardiovascular health, the […]

A number of people have asked how the recent FDA inquiries into testosterone therapy, and the related lawsuits brought by AndroGel patients, affect Low T Center. “The answer is that they don’t really relate to the medicine we practice at Low T Center,” says William Reilly, M.D., national medical director at Low T Center. “We […]